The influence of buscopan on adverse reactions to intravascular contrast media.
We have analysed the ability of prior intravenous Buscopan (hyoscine butylbromide) injection to influence the incidence and severity of adverse reactions to intravascularly administered, iodinated, ionic contrast medium in 258 consecutive digital subtraction angiographic (DSA) examinations. Adverse reactions were seen in 7.9% of the intravenous and 2.4% of the intra-arterial DSA examinations. The incidence of adverse reactions with and without prior Buscopan injection during intravenous DSA examinations was 8.2% and 7.1%, respectively and during intra-arterial DSA examinations was 5.6% and 1.5%, respectively. This difference is not statistically significant (chi 2-test). We conclude that prior intravenous injection of Buscopan has no influence on the incidence or severity of adverse reactions to intravascular contrast media.
Sharma
S
S
Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi.
Rajani
M
M
Khosla
A
A
Misra
N
N
Goulatia
R K
RK
D015901:Angiography, Digital Subtraction / Q000009:adverse effects*; D002086:Butylscopolammonium Bromide / Q000627:therapeutic use*; D003974:Diatrizoate Meglumine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D012602:Scopolamine Derivatives / Q000627:therapeutic use*
D012602:Scopolamine Derivatives; D002086:Butylscopolammonium Bromide; D003974:Diatrizoate Meglumine